Palvella Therapeutics Inc
PVLA59.040USD
+2.470+4.37%
終値 09/18, 16:00（ET）15分遅れの株価
652.96M時価総額
損失額直近12ヶ月PER
詳細情報 Palvella Therapeutics Inc 企業名
Palvella Therapeutics, Inc., formerly Pieris Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is in the Phase III SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase II trial in cutaneous venous malformations. It is also engaged in developing treatment for other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway.
企業情報
企業コードPVLA
会社名Palvella Therapeutics Inc
上場日Dec 18, 2014
最高経営責任者「CEO」Mr. Wesley H. (Wes) Kaupinen
従業員数14
証券種類Ordinary Share
決算期末Dec 18
本社所在地125 Strafford Ave
都市WAYNE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号19087
電話番号14842531461
ウェブサイトhttps://palvellatx.com/
企業コードPVLA
上場日Dec 18, 2014
最高経営責任者「CEO」Mr. Wesley H. (Wes) Kaupinen
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Jeffrey Martini, Ph.D.
Dr. Jeffrey Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Mr. Tadd S. Wessel
Mr. Tadd S. Wessel
Independent Director
Independent Director
--
--
Dr. David W. Osborne, Ph.D.
Dr. David W. Osborne, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Jeffrey Martini, Ph.D.
Dr. Jeffrey Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Aug 19
更新時刻: Tue, Aug 19
株主統計
種類
株主統計
株主統計
比率
Kaupinen (Wesley H.)
14.53%
Frazier Life Sciences Management, L.P.
6.53%
Suvretta Capital Management, LLC
6.46%
BVF Partners L.P.
6.30%
Integrated Finance Group
5.06%
他の
61.11%
株主統計
株主統計
比率
Kaupinen (Wesley H.)
14.53%
Frazier Life Sciences Management, L.P.
6.53%
Suvretta Capital Management, LLC
6.46%
BVF Partners L.P.
6.30%
Integrated Finance Group
5.06%
他の
61.11%
種類
株主統計
比率
Hedge Fund
25.08%
Individual Investor
17.79%
Investment Advisor
9.58%
Private Equity
9.24%
Investment Advisor/Hedge Fund
6.33%
Other Insider Investor
5.06%
Venture Capital
3.23%
Research Firm
1.29%
Bank and Trust
0.07%
他の
22.33%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
113
8.02M
72.53%
+1.47M
2025Q1
119
7.23M
65.51%
+2.66M
2024Q4
118
6.14M
54.71%
+5.00M
2024Q3
118
806.99K
64.03%
-218.37K
2024Q2
120
474.51K
38.85%
-479.71K
2024Q1
135
564.53K
48.12%
-430.81K
2023Q4
149
574.40K
48.95%
-409.12K
2023Q3
161
703.90K
61.81%
-282.90K
2023Q2
173
831.24K
82.60%
-68.86K
2023Q1
202
592.51K
63.79%
-198.90K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Kaupinen (Wesley H.)
1.61M
14.54%
--
--
Apr 14, 2025
Frazier Life Sciences Management, L.P.
690.01K
6.24%
+36.12K
+5.52%
Mar 31, 2025
Suvretta Capital Management, LLC
714.46K
6.46%
--
--
Mar 31, 2025
BVF Partners L.P.
696.55K
6.3%
--
--
Mar 31, 2025
Integrated Finance Group
559.95K
5.06%
+559.95K
--
Apr 14, 2025
Woodline Partners LP
194.17K
1.76%
+194.17K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
110.75K
1%
+97.85K
+758.34%
Mar 31, 2025
Samsara BioCapital, LLC
679.49K
6.15%
--
--
Mar 31, 2025
Millennium Management LLC
269.84K
2.44%
+269.84K
--
Mar 31, 2025
Adams Street Partners, LLC
409.67K
3.71%
--
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Tue, Sep 2
更新時刻: Tue, Sep 2
銘柄名
比率
ALPS Medical Breakthroughs ETF
0.24%
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Growth ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
Global X Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
詳細を見る
ALPS Medical Breakthroughs ETF
比率0.24%
iShares Micro-Cap ETF
比率0.06%
iShares Russell 2000 Growth ETF
比率0.02%
Avantis US Small Cap Equity ETF
比率0.02%
Global X Russell 2000 ETF
比率0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
iShares Russell 2000 ETF
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
日付
種類
比率
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
